Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - Άλλα παρασκευάσματα αντιαναιμικό - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

celgene europe b.v., the netherlands winthontlaan 6n, 3526kv utrecht - luspatercept - pd.inj.sol (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 75mg/vial - luspatercept 75mg - luspatercept

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

celgene europe b.v., the netherlands winthontlaan 6n, 3526kv utrecht - luspatercept - pd.inj.sol (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 25mg/vial - luspatercept 25mg - luspatercept